Alice T. Shaw, M.D., Ph.D., is the Global Head of Translational Clinical Oncology at Novartis Institutes for BioMedical Research (NIBR) where she leads early drug development in oncology. Prior to her transition to Novartis in December 2019, she was the Director of the Center for Thoracic Cancers at Massachusetts General Hospital, the Paula O'Keeffe Endowed Chair of Thoracic Oncology, and Professor of Medicine at Harvard Medical School.
At Massachusetts General Hospital, Dr. Shaw’s research focused on a variety of different molecularly-defined subsets of non-small cell lung cancer (NSCLC) and specifically elucidating mechanisms of resistance to targeted therapies. Based on her research, she helped develop numerous targeted therapies for patients with oncogene-driven NSCLC, four of which are now FDA approved therapies: crizotinib (for both ALK- and ROS1-positive NSCLC), ceritinib, alectinib and most recently lorlatinib for ALK-positive NSCLC. Prior to her transition to Novartis, Dr. Shaw’s efforts focused on developing novel combinatorial strategies aimed at overcoming drug resistance. Dr. Shaw continues to see patients in the Thoracic Oncology clinic at Mass General.